Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT8006 + bevacizumab versus bevacizumab maintenance in platinum-sensitive recurrent ovarian cancer
CTR20252907Phase 3Active
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of BAT8006, bevacizumab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Bio-Thera Solutions, Ltd.. Started Sep 2025; status: active.
02
Drugs
BAT8006bevacizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20252907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252907.